Latest News and Press Releases

Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.

Analysis examines MEDVi's compounded GLP-1 semaglutide telehealth model, FDA compounding framework, and prescription weight loss trends for 2026.

Omada Health’s new analysis adds to existing evidence that its GLP-1 companion program helps drive lasting, long-term weight loss

Industry analysis examines how patients verify telehealth GLP-1 platforms after FDA oral semaglutide approval. Direct Meds included as case study.

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.

FDA approves oral Wegovy pill Dec 2025. Analysis compares FDA-approved injectable, oral, and compounded semaglutide access pathways for 2026.

SkinnyRx offers compounded semaglutide in 3 forms starting at $199/month through licensed providers as New Year weight loss demand approaches.

U.S. JPML has created a new multidistrict litigation for lawsuits alleging that GLP-1 receptor agonist drugs cause NAION, a serious vision injury.

Austin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Anti-Obesity Drugs Market Size & Growth Analysis: According to SNS Insider, the Anti-Obesity Drugs Market size was valued at $5.75 billion in 2024 and...

Treating people living with HIV and metabolic dysfunction-associated MASLD with semaglutide significantly improved biomarkers of cardiovascular risk.